LY6K and esophageal squamous cell carcinoma: Additionally, LY6K is a target for cancer vaccine therapies because stimulating cytotoxic T lymphocytes by endogenously expressed LY6K presents a specific cytotoxic activity against lung and esophageal squamous cell carcinoma [19].